Pharma stock jumps after receiving approval for eluxadoline tablets from USFDAPharma stock jumps after receiving approval for eluxadoline tablets from USFDA

Introduction:

Leading pharma company has received final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg. The drug, used to treat irritable bowel syndrome with diarrhea (IBS-D), will be produced at its Ahmedabad facility, strengthening its growing regulatory portfolio.

Also Read: Transformer stock jumps 6% after receiving order worth ₹726 Cr from Gujarat Energy Transmission

Share price movement of Zydus Lifesciences:

On March 17, 2025, Zydus Lifesciences Ltd opened at ₹899.40, up 1.91% from its previous close of ₹882.55. The stock reached a high of ₹901.55 (2.15%) and a low of ₹888.00. By 10:32 AM, it traded at ₹896.40, a 1.57% increase, with a market cap of ₹90,198.81 crore.

Zydus Gains USFDA Approval for Eluxadoline Tablets:

Zydus Lifesciences Ltd. has secured final approval from the USFDA to manufacture Eluxadoline Tablets, 75 mg and 100 mg. The drug, a mu-opioid receptor agonist, is used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults, boosting Zydus portfolio.

Eluxadoline tablets will be produced at Zydus Ahmedabad facility. As one of the first ANDA applicants with a Paragraph IV certification, Zydus is entitled to 180 days of shared generic drug exclusivity. The US market for Eluxadoline tablets was valued at USD 243.7 million as of January 2025.

With this approval, Zydus now holds 419 approvals, having filed 483 ANDAs since FY 2003-04. This milestone strengthens its US presence and reinforces its commitment to affordable healthcare. The company continues to expand its global reach with strategic regulatory approvals.

Recent news on Zydus Lifesciences:

As of March 11, 2025, Zydus Lifesciences Ltd entered exclusive negotiations to acquire an 85.6% stake in France-based Amplitude Surgical SA for €256.8 million, aiming to expand into the global medical devices market with a potential full acquisition of €300 million.

Stock performance of Zydus Lifesciences for Period of 1 week, 6 months, and 1 year:

Zydus Lifesciences Ltd has faced a decline in stock performance, with a 1.19% drop over the past week. The stock fell 18.2% in six months and 10.2% over the past year, reflecting ongoing market challenges and investor sentiment.

Also Read: Agrochemical stocks with high piotroski score of 9 to watch out for

Shareholding pattern of Zydus Lifesciences:

Particulars	Dec 2024	Sep 2024	Jun 2024
Promoter	75.00%	75.00%	75.00%
FII	8%	8%	6%
DII	11%	11%	13%
Public	6.90%	6.90%	6.80%

About Zydus Lifesciences:

Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) emerged from Cadila Healthcare’s restructuring in 1995. Growing from ₹250 crore revenue to ₹14,253 crore in FY20, it remains committed to innovation, addressing healthcare needs, and fostering healthier global communities through continuous advancements.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.